ContractDevelopment and Supplemental Agreement to Amended and Restated License Agreement • May 23rd, 2013 • Alkermes Plc. • Pharmaceutical preparations • New York
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.
ContractLicense Agreement • May 23rd, 2013 • Alkermes Plc. • Pharmaceutical preparations • New Jersey
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.
ContractLicense Agreement • May 23rd, 2013 • Alkermes Plc. • Pharmaceutical preparations
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.
July 31, 2003 Janssen Pharmaceutica N.V. Turnhoutseweg 30 Attention: Guy VercauterenLicense Agreement • May 23rd, 2013 • Alkermes Plc. • Pharmaceutical preparations
RE: First Amendment to the License Agreement by and among Elan Drug Delivery, Inc. (formerly Elan Pharmaceutical Research Corp.) and Elan Pharma International Limited and Janssen Pharmaceutica NV dated 31 March 1999 (“the License Agreement”)
ContractSupply Agreement • May 23rd, 2013 • Alkermes Plc. • Pharmaceutical preparations • New York
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.
AMENDMENT NO. 3 AND WAIVER TO AMENDED AND RESTATED CREDIT AGREEMENTAmendment No. 3 and Waiver to Amended and Restated Credit Agreement • May 23rd, 2013 • Alkermes Plc. • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 3 AND WAIVER TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) dated as of May 22, 2013 is entered into by and among Alkermes, Inc., a corporation organized under the laws of the Commonwealth of Pennsylvania (the “Borrower”), Alkermes plc, a company incorporated under the laws of the Republic of Ireland (“Holdings”), Alkermes Pharma Ireland Limited, a private limited company organized under the laws of the Republic of Ireland (“Intermediate Holdco”), Alkermes US Holdings, Inc. (“Holdco”), Morgan Stanley Senior Funding, Inc., as administrative agent (in such capacity, the “Administrative Agent”) and as collateral agent (in such capacity, the “Collateral Agent”), and the undersigned lenders. Capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Credit Agreement (as defined below).
